The Case for Stand-alone MIGS Gets Stronger
With a favorable safety profile and ability to be easily incorporated into practices, minimally invasive glaucoma surgery (MIGS) has been welcomed by ophthalmologists. However, MIGS procedures currently are approved by the US Food and Drug Administration (FDA) to be performed only in conjunction with cataract surgery. Studies that can substantiate the benefits of MIGS as a stand-alone procedure may help MIGS gain wider approval.
@bubbly Thankfully, the recently published ROMEO study has arrived at such findings. Investigators behind this multicenter, retrospective study assessed the intraocular pressure (IOP) lowering effect of canaloplasty and trabeculotomy with the OMNI System (Sight Sciences, Inc, Menlo Park, California) in 48 pseudophakic patients with open-angle glaucoma. Patients were stratified in equal numbers into two groups based on their baseline IOP (> 18 mm Hg or ≤ 18 mm Hg). Primary success was defined as IOP ≤ 18 mm Hg and ≥ 6 mm Hg or a 20% reduction from preoperative IOP with same or fewer number of ocular hypotensive medications and no additional IOP-lowering surgery or laser.